• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

安普那韦与 HIV-1 蛋白酶及其耐药突变体形成复合物,改变疏水区簇。

Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.

机构信息

Department of Biology, Molecular Basis of Disease Program, Georgia State University, Atlanta, GA, USA.

出版信息

FEBS J. 2010 Sep;277(18):3699-714. doi: 10.1111/j.1742-4658.2010.07771.x. Epub 2010 Aug 2.

DOI:10.1111/j.1742-4658.2010.07771.x
PMID:20695887
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2975871/
Abstract

The structural and kinetic effects of amprenavir (APV), a clinical HIV protease (PR) inhibitor, were analyzed with wild-type enzyme and mutants with single substitutions of V32I, I50V, I54V, I54M, I84V and L90M that are common in drug resistance. Crystal structures of the APV complexes at resolutions of 1.02-1.85 Å reveal the structural changes due to the mutations. Substitution of the larger side chains in PR(V32I) , PR(I54M) and PR(L90M) resulted in the formation of new hydrophobic contacts with flap residues, residues 79 and 80, and Asp25, respectively. Mutation to smaller side chains eliminated hydrophobic interactions in the PR(I50V) and PR(I54V) structures. The PR(I84V)-APV complex had lost hydrophobic contacts with APV, the PR(V32I)-APV complex showed increased hydrophobic contacts within the hydrophobic cluster and the PR(I50V) complex had weaker polar and hydrophobic interactions with APV. The observed structural changes in PR(I84V)-APV, PR(V32I)-APV and PR(I50V)-APV were related to their reduced inhibition by APV of six-, 10- and 30-fold, respectively, relative to wild-type PR. The APV complexes were compared with the corresponding saquinavir complexes. The PR dimers had distinct rearrangements of the flaps and 80's loops that adapt to the different P1' groups of the inhibitors, while maintaining contacts within the hydrophobic cluster. These small changes in the loops and weak internal interactions produce the different patterns of resistant mutations for the two drugs.

摘要

分析了安普那韦(APV),一种临床 HIV 蛋白酶(PR)抑制剂,对野生型酶和具有单个取代的 V32I、I50V、I54V、I54M、I84V 和 L90M 突变体的结构和动力学影响,这些突变是耐药性中常见的。分辨率为 1.02-1.85 Å 的 APV 复合物的晶体结构揭示了由于突变引起的结构变化。PR(V32I)、PR(I54M) 和 PR(L90M) 的较大侧链取代导致与瓣状残基、残基 79 和 80 以及 Asp25 分别形成新的疏水性接触。较小侧链的突变消除了 PR(I50V)和 PR(I54V)结构中的疏水性相互作用。PR(I84V)-APV 复合物与 APV 失去了疏水性接触,PR(V32I)-APV 复合物在疏水区内显示出增加的疏水性接触,而 PR(I50V)复合物与 APV 的极性和疏水性相互作用较弱。观察到的 PR(I84V)-APV、PR(V32I)-APV 和 PR(I50V)-APV 中的结构变化与它们对 APV 的抑制作用分别降低了 6 倍、10 倍和 30 倍有关,相对于野生型 PR。将 APV 复合物与相应的沙奎那韦复合物进行了比较。PR 二聚体的瓣状结构和 80 环有明显的重排,以适应抑制剂的不同 P1'基团,同时保持疏水簇内的接触。这两种药物的耐药突变模式产生了这些小的环和弱的内部相互作用的变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/e9f6a2e02039/nihms231043f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/9ca2ed09db66/nihms231043f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/10997d471f21/nihms231043f2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/c62d0f97a0cc/nihms231043f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/3385eae3f37e/nihms231043f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/e9f6a2e02039/nihms231043f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/9ca2ed09db66/nihms231043f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/10997d471f21/nihms231043f2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/c62d0f97a0cc/nihms231043f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/3385eae3f37e/nihms231043f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecd3/2975871/e9f6a2e02039/nihms231043f5.jpg

相似文献

1
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.安普那韦与 HIV-1 蛋白酶及其耐药突变体形成复合物,改变疏水区簇。
FEBS J. 2010 Sep;277(18):3699-714. doi: 10.1111/j.1742-4658.2010.07771.x. Epub 2010 Aug 2.
2
Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.瓣突变对HIV-1蛋白酶结构以及沙奎那韦和达芦那韦抑制作用的影响。
J Mol Biol. 2008 Aug 1;381(1):102-15. doi: 10.1016/j.jmb.2008.05.062. Epub 2008 Jul 1.
3
Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.HIV-1 蛋白酶突变体对安普那韦耐药的能量基础。
J Comput Aided Mol Des. 2012 Feb;26(2):215-32. doi: 10.1007/s10822-012-9550-5. Epub 2012 Feb 14.
4
A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.一项关于 HIV-1 蛋白酶与达芦那韦、安普那韦、茚地那韦和沙奎那韦复合物因 flap 突变 I50V 导致耐药机制的贡献:系统 MM-PBSA 和热力学积分研究。
J Chem Inf Model. 2013 Aug 26;53(8):2141-53. doi: 10.1021/ci4002102. Epub 2013 Jul 24.
5
Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.对来自一株对安普那韦耐药的1型人类免疫缺陷病毒突变体的蛋白酶进行结构和动力学分析,该突变体对沙奎那韦耐药但对安普那韦重新敏感。
J Virol. 2000 Aug;74(16):7636-41. doi: 10.1128/jvi.74.16.7636-7641.2000.
6
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.耐药性突变对HIV-1蛋白酶动力学特性的影响以及安普那韦和达芦那韦的抑制作用。
Sci Rep. 2015 May 27;5:10517. doi: 10.1038/srep10517.
7
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.不同抑制剂与HIV-1蛋白酶活性位点天冬氨酰残基的相互作用及其与胃蛋白酶的可能关联。
Proteins. 2009 May 15;75(3):556-68. doi: 10.1002/prot.22271.
8
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.HIV-1 和 HIV-2 蛋白酶对临床抑制剂特异性的关键差异。
Protein Sci. 2012 Mar;21(3):339-50. doi: 10.1002/pro.2019. Epub 2012 Jan 24.
9
Decoding drug resistant mechanism of V32I, I50V and I84V mutations of HIV-1 protease on amprenavir binding by using molecular dynamics simulations and MM-GBSA calculations.基于分子动力学模拟和 MM-GBSA 计算方法,解析 HIV-1 蛋白酶 V32I、I50V 和 I84V 突变体对安普那韦结合的耐药机制。
SAR QSAR Environ Res. 2022 Oct;33(10):805-831. doi: 10.1080/1062936X.2022.2140708. Epub 2022 Nov 2.
10
Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.HIV-1 蛋白酶突变体 50 位残基致安普那韦/达芦那韦和阿扎那韦耐药的结构和热力学基础。
J Virol. 2013 Apr;87(8):4176-84. doi: 10.1128/JVI.03486-12. Epub 2013 Jan 30.

引用本文的文献

1
Regioselective intermolecular carboamination of allylamines nucleopalladation: empowering three-component synthesis of vicinal diamines.烯丙胺的区域选择性分子间碳胺化反应:亲核钯化作用助力邻二胺的三组分合成
Chem Sci. 2024 Nov 29;16(1):386-392. doi: 10.1039/d4sc07630c. eCollection 2024 Dec 18.
2
Identification of steroidal cardenolides from Calotropis procera as novel HIV-1 PR inhibitors: A molecular docking & molecular dynamics simulation study.从牛角瓜中鉴定出甾体卡烯内酯类化合物作为新型 HIV-1 PR 抑制剂:分子对接和分子动力学模拟研究。
Indian J Med Res. 2024 Jul;160(1):78-86. doi: 10.25259/IJMR_2115_23.
3
Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.振荡模式下收集的X射线衍射数据的处理。
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.对蛋白酶抑制剂地瑞那韦耐药的人类免疫缺陷病毒临床分离株的分子特征分析
J Virol. 2009 Sep;83(17):8810-8. doi: 10.1128/JVI.00451-09. Epub 2009 Jun 17.
3
Update of the Drug Resistance Mutations in HIV-1.人类免疫缺陷病毒1型耐药突变的更新
近年来分子连接酶降解剂抗癌机制的研究进展:聚焦于 RBM39 降解的合成磺胺类药物,如依达司他、E7820、他昔舒仑和氯喹喔啉磺胺类药物。
Genes Genomics. 2024 Dec;46(12):1345-1361. doi: 10.1007/s13258-024-01565-z. Epub 2024 Sep 13.
4
Enthalpic Classification of Water Molecules in Target-Ligand Binding.水合分子在靶标-配体结合中的焓分类。
J Chem Inf Model. 2024 Aug 26;64(16):6583-6595. doi: 10.1021/acs.jcim.4c00794. Epub 2024 Aug 12.
5
Design of substituted tetrahydrofuran derivatives for HIV-1 protease inhibitors: synthesis, biological evaluation, and X-ray structural studies.设计取代的四氢呋喃衍生物作为 HIV-1 蛋白酶抑制剂:合成、生物评价和 X 射线结构研究。
Org Biomol Chem. 2024 Sep 18;22(36):7354-7372. doi: 10.1039/d4ob00506f.
6
Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities.作为抗病毒活性的小环氧杂和氮杂杂环系统的结构和合成方面。
Viruses. 2023 Aug 28;15(9):1826. doi: 10.3390/v15091826.
7
Chemical features and machine learning assisted predictions of protein-ligand short hydrogen bonds.化学特征和机器学习辅助的蛋白-配体短氢键预测。
Sci Rep. 2023 Aug 23;13(1):13741. doi: 10.1038/s41598-023-40614-7.
8
Theoretical Study on the Alkylimino-Substituted Sulfonamides with Potential Biological Activity.具有潜在生物活性的烷基脒基取代磺酰胺的理论研究。
J Phys Chem B. 2023 Aug 3;127(30):6620-6627. doi: 10.1021/acs.jpcb.3c01965. Epub 2023 Jul 21.
9
Chemical Features and Machine Learning Assisted Predictions of Protein-Ligand Short Hydrogen Bonds.蛋白质-配体短氢键的化学特征及机器学习辅助预测
Res Sq. 2023 May 15:rs.3.rs-2895170. doi: 10.21203/rs.3.rs-2895170/v1.
10
Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation.探索伊马替尼和尼罗替尼衍生模板作为 HIV-1 蛋白酶抑制剂的 P2-配体:设计、合成、蛋白质 X 射线结构研究和生物学评价。
Eur J Med Chem. 2023 Jul 5;255:115385. doi: 10.1016/j.ejmech.2023.115385. Epub 2023 Apr 21.
Top HIV Med. 2008 Dec;16(5):138-45.
4
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.柔性环状醚/聚醚作为新型HIV-1蛋白酶抑制剂的P2配体:设计、合成、生物学评价及蛋白质-配体X射线研究
J Med Chem. 2008 Oct 9;51(19):6021-33. doi: 10.1021/jm8004543. Epub 2008 Sep 11.
5
Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.瓣突变对HIV-1蛋白酶结构以及沙奎那韦和达芦那韦抑制作用的影响。
J Mol Biol. 2008 Aug 1;381(1):102-15. doi: 10.1016/j.jmb.2008.05.062. Epub 2008 Jul 1.
6
SHELXL: high-resolution refinement.SHELXL:高分辨率精修。
Methods Enzymol. 1997;277:319-43.
7
Toward an AIDS vaccine.迈向艾滋病疫苗。
Science. 2008 May 9;320(5877):760-4. doi: 10.1126/science.1152622.
8
A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket.眼中一戳:通过其翼片识别口袋抑制HIV-1蛋白酶
Biopolymers. 2008 Aug;89(8):643-52. doi: 10.1002/bip.20993.
9
Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.活性位点D25N突变对成熟HIV-1蛋白酶的结构、稳定性及配体结合的影响
J Biol Chem. 2008 May 9;283(19):13459-70. doi: 10.1074/jbc.M708506200. Epub 2008 Feb 15.
10
Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.强效新型抗病毒化合物对耐药突变体和野生型HIV-1蛋白酶表现出相似的抑制作用和结构相互作用。
J Med Chem. 2007 Sep 6;50(18):4509-15. doi: 10.1021/jm070482q. Epub 2007 Aug 16.